Literature DB >> 28559651

The 2017 Focused Update of the Guidelines of the Taiwan Society of Cardiology (TSOC) and the Taiwan Hypertension Society (THS) for the Management of Hypertension.

Chern-En Chiang1, Tzung-Dau Wang2, Tsung-Hsien Lin3, Hung-I Yeh4, Ping-Yen Liu5, Hao-Min Cheng6, Ting-Hsing Chao7, Chen-Huan Chen8, Kou-Gi Shyu9, Kwo-Chang Ueng10, Chung-Yin Chen11, Pao-Hsien Chu12, Shih-Hsien Sung13, Kang-Ling Wang14, Yi-Heng Li7, Kuo-Yang Wang15, Fu-Tien Chiang16, Wen-Ter Lai3,17, Jyh-Hong Chen18, Wen-Jone Chen2,19, San-Jou Yeh20, Ming-Fong Chen21, Shing-Jong Lin22, Jiunn-Lee Lin2.   

Abstract

Hypertension (HT) is the most important risk factor for cardiovascular diseases. Over the past 25 years, the number of individuals with hypertension and the estimated associated deaths has increased substantially. There have been great debates in the past few years on the blood pressure (BP) targets. The 2013 European Society of Hypertension and European Society of Cardiology HT guidelines suggested a unified systolic BP target of 140 mmHg for both high-risk and low-risk patients. The 2014 Joint National Committee report further raised the systolic BP targets to 150 mmHg for those aged ≥ 60 years, including patients with stroke or coronary heart disease, and raised the systolic BP target to 140 mmHg for diabetes. Instead, the 2015 Hypertension Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society suggested more aggressive BP targets of < 130/80 mmHg for patients with diabetes, coronary heart disease, chronic kidney disease with proteinuria, and atrial fibrillation patients on antithrombotic therapy. Based on the main findings from the Systolic Blood Pressure Intervention Trial (SPRINT) and several recent meta-analyses, the HT committee members of the Taiwan Society of Cardiology and the Taiwan Hypertension Society convened and finalized the revised BP targets for management of HT. We suggested a new systolic BP target to < 120 mmHg for patients with coronary heart disease, chronic kidney disease with an eGFR of 20-60 ml/min/1.73 m2, and elderly patients aged ≥ 75 years, using unattended automated office BP measurement. When traditional office BP measurement is applied, we suggested BP target of < 140/90 mmHg for elderly patients with an age ≥ 75 years. Other BP targets with traditional office BP measurement remain unchanged. With these more aggressive BP targets, it is foreseeable that the cardiovascular events will decrease substantially in Taiwan.

Entities:  

Keywords:  Guidelines; Hypertension; Taiwan Hypertension Society; Taiwan Society of Cardiology

Year:  2017        PMID: 28559651      PMCID: PMC5445238          DOI: 10.6515/acs20170421a

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  69 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Recommendations for treating hypertension: what are the right goals and purposes?

Authors:  Eric D Peterson; J Michael Gaziano; Philip Greenland
Journal:  JAMA       Date:  2014-02-05       Impact factor: 56.272

Review 3.  Outcomes of Intensive Blood Pressure Lowering in Older Hypertensive Patients.

Authors:  Chirag Bavishi; Sripal Bangalore; Franz H Messerli
Journal:  J Am Coll Cardiol       Date:  2017-02-07       Impact factor: 24.094

Review 4.  Pharmacotherapy of Hypertension in Chronic Dialysis Patients.

Authors:  Panagiotis I Georgianos; Rajiv Agarwal
Journal:  Clin J Am Soc Nephrol       Date:  2016-10-24       Impact factor: 8.237

5.  The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy.

Authors:  Doreen M Rabi; Stella S Daskalopoulou; Raj S Padwal; Nadia A Khan; Steven A Grover; Daniel G Hackam; Martin G Myers; Donald W McKay; Robert R Quinn; Brenda R Hemmelgarn; Lyne Cloutier; Peter Bolli; Michael D Hill; Thomas Wilson; Brian Penner; Ellen Burgess; Maxime Lamarre-Cliché; Donna McLean; Ernesto L Schiffrin; George Honos; Karen Mann; Guy Tremblay; Alain Milot; Arun Chockalingam; Simon W Rabkin; Martin Dawes; Rhian M Touyz; Kevin D Burns; Marcel Ruzicka; Norman R C Campbell; Michel Vallée; G V Ramesh Prasad; Marcel Lebel; Tavis S Campbell; M Patrice Lindsay; Robert J Herman; Pierre Larochelle; Ross D Feldman; J Malcolm O Arnold; Gordon W Moe; Jonathan G Howlett; Luc Trudeau; Simon L Bacon; Robert J Petrella; Richard Lewanczuk; James A Stone; Denis Drouin; Jean-Martin Boulanger; Mukul Sharma; Pavel Hamet; George Fodor; George K Dresser; S George Carruthers; George Pylypchuk; Richard E Gilbert; Lawrence A Leiter; Charlotte Jones; Richard I Ogilvie; Vincent Woo; Philip A McFarlane; Robert A Hegele; Luc Poirier; Sheldon W Tobe
Journal:  Can J Cardiol       Date:  2011 Jul-Aug       Impact factor: 5.223

6.  Diastolic Blood Pressure, Subclinical Myocardial Damage, and Cardiac Events: Implications for Blood Pressure Control.

Authors:  John W McEvoy; Yuan Chen; Andreea Rawlings; Ron C Hoogeveen; Christie M Ballantyne; Roger S Blumenthal; Josef Coresh; Elizabeth Selvin
Journal:  J Am Coll Cardiol       Date:  2016-08-30       Impact factor: 24.094

7.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

8.  2015 guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension.

Authors:  Chern-En Chiang; Tzung-Dau Wang; Kwo-Chang Ueng; Tsung-Hsien Lin; Hung-I Yeh; Chung-Yin Chen; Yih-Jer Wu; Wei-Chuan Tsai; Ting-Hsing Chao; Chen-Huan Chen; Pao-Hsien Chu; Chia-Lun Chao; Ping-Yen Liu; Shih-Hsien Sung; Hao-Min Cheng; Kang-Ling Wang; Yi-Heng Li; Fu-Tien Chiang; Jyh-Hong Chen; Wen-Jone Chen; San-Jou Yeh; Shing-Jong Lin
Journal:  J Chin Med Assoc       Date:  2014-12-26       Impact factor: 2.743

9.  Automated office blood pressure is associated with urine albumin excretion in hypertensive subjects.

Authors:  Emmanuel A Andreadis; Gerasimos D Agaliotis; Epameinondas T Angelopoulos; Athanasios P Tsakanikas; George N Kolyvas; George P Mousoulis
Journal:  Am J Hypertens       Date:  2012-06-14       Impact factor: 2.689

10.  The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.

Authors:  S Klahr; A S Levey; G J Beck; A W Caggiula; L Hunsicker; J W Kusek; G Striker
Journal:  N Engl J Med       Date:  1994-03-31       Impact factor: 91.245

View more
  31 in total

1.  Appropriate Use of Dual Antiplatelet Therapy.

Authors:  Kang-Ling Wang; Tzung-Dau Wang
Journal:  Acta Cardiol Sin       Date:  2019-07       Impact factor: 2.672

2.  Brain Perfusion Matters: From Pituitary Function to Blood Pressure Control during Acute Ischemic Stroke.

Authors:  Tzung-Dau Wang
Journal:  Acta Cardiol Sin       Date:  2018-11       Impact factor: 2.672

3.  Our Stance towards the 2017 ACC/AHA High Blood Pressure Clinical Practice Guideline: Has the Pendulum Swung Too Far?

Authors:  Tzung-Dau Wang
Journal:  Acta Cardiol Sin       Date:  2018-01       Impact factor: 2.672

4.  From Real-World Evidence to Consensus of Renal Denervation in Taiwan: A Call for the Incorporation of Ambulatory Blood Pressure Monitoring after Witnessed Intake of Medications.

Authors:  Tzung-Dau Wang
Journal:  Acta Cardiol Sin       Date:  2019-11       Impact factor: 2.672

Review 5.  Evolution of Blood Pressure Clinical Practice Guidelines: A Personal Perspective.

Authors:  Paul K Whelton
Journal:  Can J Cardiol       Date:  2019-02-27       Impact factor: 5.223

6.  Effect of Radiofrequency-Based Renal Denervation: The Impact of Unplanned Medication Change from a Systematic Review and Meta-Analysis.

Authors:  Lawrence Yu-Min Liu; Po-Lin Lin; Feng-Ching Liao; Shu-I Lin; Wei-Ru Chiou; Yih-Jer Wu; Ying-Hsiang Lee
Journal:  Acta Cardiol Sin       Date:  2019-03       Impact factor: 2.672

7.  Direct Comparison of Low-Dose Dabigatran and Rivaroxaban for Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation.

Authors:  Shih-Wei Meng; Ting-Tse Lin; Min-Tsun Liao; Ho-Min Chen; Chao-Lun Lai
Journal:  Acta Cardiol Sin       Date:  2019-01       Impact factor: 2.672

8.  Gabapentin Reduces Blood Pressure and Heart Rate through the Nucleus Tractus Solitarii.

Authors:  Hsin-Hung Chen; Yih-Do Li; Pei-Wen Cheng; Yi-Chien Fang; Chi-Cheng Lai; Ching-Jiunn Tseng; Jun-Yen Pan; Tung-Chen Yeh
Journal:  Acta Cardiol Sin       Date:  2019-11       Impact factor: 2.672

9.  Efficacy and Safety of Renal Denervation for Patients with Uncontrolled Hypertension in Taiwan: 3-Year Results From the Global SYMPLICITY Registry-Taiwan (GSR-Taiwan).

Authors:  Chih-Kuo Lee; Tzung-Dau Wang; Ying-Hsiang Lee; Martin Fahy; Cheng-Han Lee; Shih-Hsien Sung; Hsien-Li Kao; Yen-Wen Wu; Tsung-Hsien Lin
Journal:  Acta Cardiol Sin       Date:  2019-11       Impact factor: 2.672

Review 10.  Asian management of hypertension: Current status, home blood pressure, and specific concerns in Taiwan.

Authors:  Hao-Min Cheng; Hung-Ju Lin; Tzung-Dau Wang; Chen-Huan Chen
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-12-09       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.